GRAIL, Inc. Accrued Marketing Costs, Current
GRAIL, Inc. (GRAL) had Accrued Marketing Costs, Current of $605.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2025-03-05
- 2024-12-31: Accrued Marketing Costs, Current $605.00K.
- 2024-09-30: Accrued Marketing Costs, Current $1.21M.
- 2024-06-30: Accrued Marketing Costs, Current $650.00K.
- 2023-12-31: Accrued Marketing Costs, Current $1.88M.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2024-12-31 | $605.00K 10-K · filed 2025-03-05 |
| 2024-09-30 | $1.21M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $650.00K 10-Q · filed 2024-08-13 |
| 2023-12-31 | $1.88M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |